FAQ - 製薬/生命科学(ライフサイエンス)における微粒子測定
製品、展示会等に関するお問い合わせは、こちらをクリックしてください- 質問
We have a filling line which includes the following elements; vial in-feed turntable, filling, stopper handling and capping stations. I understand that the clean space is required to be certified and qualified however, from your experience and what you observe in industry, how many and what locations are monitored on a routine basis for the filling line application indicated above. For example, is it industry practice that monitoring continuously takes place at the vial in-feed, filling and stoppering zones? - 回答
There are several areas that constantly come up for review when realizing what processes to monitor.
Steriliser tunnel outfeed
This may also be where glassware is loaded on manual systems. This is of a concern as particulates may fall into exposed glassware prior to filling, so surety over the environment between end of depyrogenation and filling is important. Typically even if a conveyor moves the glass from the carousel to the point of fill it is the carousel where any residence time occurs and is the more important location for monitoring.
Point of fill (POF)
Possibly the most important area as far as audits are concerned, where product is exposed and interventions from personnel may occur. This is the whole 12" from POF that the FDA retain as the guiding measure of monitoring.
Stoppering
The point at which again process and product come together. If the distance between the POF and stoppering is relatively short then a single point located strategically between POF and stoppering will suffice, if the distance is approximately 1 m then a sample point at the stoppering point is required. There is much debate over the monitoring of the stopper bowl while the stoppers are being fed; the same rationale as the sterilizer tunnel is used as contaminated stoppers could impact the finished product, however the particulate cleanliness of stoppers is always a concern and monitoring of a clean shedding process is not required.
These are the key areas, along with a suitable point in the background that would cover the application in the paper and are the minimum that would be expected, although I have seen more they become problematic trying to correlate real issues with false positives. The goal would be to be able to quantify personnel interventions and from that ascertain the risk to finished product.
For more information, see Choosing the Most Suitable Non-viable Sample Point Locations
Contact us if you need more information or have questions.
- カスタマー サポート
- 技術サポート
- よくある質問
- 気中微粒子
- 液中微粒子モニタリング
- 製薬/生命科学(ライフサイエンス)における微粒子測定
- Particle Count Frequency
- Counter Height
- Room Qualification
- Monitoring Time
- ISO Hospitals
- CleanroomVerification
- ISO8
- GMP testing
- IQ/OQ
- Support Docs
- Powder FMS
- Powder SOP
- Powder Collection Height
- Stopper Bowl
- Powder Regulations
- Filling Line
- Airnet Class 5
- Capping Station
- Cubic Meter Certification
- Isolated Excursions
- Sample point placement
- Dry Powder FMS
- IV Solutions
- Pharmaceutical Net
- EU GMP Annex I 2007
- 1986 Specifications
- 1986 v 1995 Specs
- パーティクルカウンタサービス
- AMC分子状ケミカル汚染対策について
- ガス分析
- 全般
- ニュースレター
- 技術資料
- パーティクル カウンタ
- 分子モニタ
- サービス
- レンタル&リース
- ニュース
当ウェブサイト上の情報は予告無く変更される場合があります。